**Cogent Biosciences Relocates Headquarters to BXP’s 180 CityPoint in Waltham**
Cogent Biosciences, Inc. has secured a 31,518-square-foot lease at 180 CityPoint, a Class A office and life sciences building in Waltham, Massachusetts. The property is owned and operated by BXP. The newly leased space will serve as Cogent’s corporate headquarters, marking a relocation from its previous location at 275 Wyman Street. This move comes as the biotech firm prepares to commercialize its first product.
The tenant, Cogent Biosciences, was represented by Cushman & Wakefield’s Michael O’Leary, Kevin McNamara, Thomas Ashe, and Ross Gaudet. BXP was self-represented in the transaction, with Pat Mulvihill, Senior Vice President of Leasing, and Casey Torto, Leasing Manager for BXP’s Boston region, leading the efforts.
“This headquarters lease underscores the shift of innovative biotech companies coming to Waltham, which offers the high-quality space and accessibility that companies primarily once looked for in Cambridge,” said Kevin McNamara of Cushman & Wakefield. “Cogent will benefit from a state-of-the-art environment that supports the firm’s culture, recruitment, and long-term success.”
In addition to Cogent’s lease, BXP recently announced that Amplitude Vascular Systems has signed a lease for 38,000 square feet at the same property, with plans to relocate from the Seaport District to 180 CityPoint in Waltham.
This trend highlights Waltham’s growing appeal as a hub for life sciences and biotech companies seeking high-quality space with greater flexibility and access.
